Bulk Manufacturer of Controlled Substances Application: Promega Corporation
Published Date: 2/2/2026
Notice
Summary
Promega Corporation wants to make large amounts of psilocybin and psilocyn, two controlled substances, to sell as ingredients for medicines. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 3, 2026. This move could boost medicine development but also means Promega will handle some powerful substances under strict rules.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Promega Seeks to Make Schedule I APIs
On January 7, 2026, Promega Corporation (3075 Sub Zero Parkway, Fitchburg, Wisconsin) applied to be registered to bulk manufacture psilocybin (code 7437) and psilocyn (code 7438), both listed as Schedule I. The company says it plans to make these substances as Active Pharmaceutical Ingredients (APIs) for sale to its customers, and the registration would not authorize any other activities for those drug codes. Comments or requests for a hearing are due by April 3, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-01939 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on May 12, 2026, with part of it open to the public and part closed to protect private info and trade secrets. They’ll review grant applications in the closed session and discuss programs openly afterward. Anyone can watch the open part online and send in comments up to 15 days before the meeting.
Next: 2026-01941 — Center for Scientific Review; Notice of Closed Meeting
The NIH’s Center for Scientific Review is holding a secret virtual meeting on February 19, 2026, to review important grant applications about brain aging and cognitive disorders. This meeting was delayed by a government shutdown but is now urgent to keep research funding on track. Scientists and public health depend on these quick decisions to support vital medical research.